Literature DB >> 1378901

The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.

J A Lowe1, S E Drozda, R M Snider, K P Longo, S H Zorn, J Morrone, E R Jackson, S McLean, D K Bryce, J Bordner.   

Abstract

We describe the structure-activity relationship development of a series of quinuclidines which culminated in the first potent, selective, nonpeptide substance P (SP) antagonist, (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)methyl]-1- azabicyclo[2.2.2]octan-3-amine, 3 (CP-96,345). Compound 3 is a potent displacer of [3H]SP binding in human IM-9 cells and blocks SP-induced and capsaicin-induced plasma extravasation, as well as SP-induced salivation in the rat in vivo. This compound may both help to further our understanding of the interactions of small molecules with peptide receptors and serve to evaluate the therapeutic potential of a SP antagonist.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378901     DOI: 10.1021/jm00092a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes.

Authors:  Anders Poulsen; Tommy Liljefors; Klaus Gundertofte; Berith Bjørnholm
Journal:  J Comput Aided Mol Des       Date:  2002-04       Impact factor: 3.686

3.  Evidence for tonic activation of NK-1 receptors during the second phase of the formalin test in the Rat.

Authors:  J L Henry; K Yashpal; G M Pitcher; J Chabot; T J Coderre
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

4.  Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

Authors:  U Gether; Y Yokota; X Emonds-Alt; J C Brelière; J A Lowe; R M Snider; S Nakanishi; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Non-specific activity of (+/-)-CP-96,345 in models of pain and inflammation.

Authors:  A Nagahisa; R Asai; Y Kanai; A Murase; M Tsuchiya-Nakagaki; T Nakagaki; T C Shieh; K Taniguchi
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

6.  The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol.

Authors:  Pia Steensland; Jeffrey A Simms; Carsten K Nielsen; Joan Holgate; Jade J Bito-Onon; Selena E Bartlett
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.